Back

Increased risk of stroke in non-rheumatic valvular disease associated with antiphospholipid syndrome (APS): a US nationwide study 2017-2019

2 September 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Diversity and specific populations in valvular heart disease Clinical ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Sujana Sanka

The Brooklyn Hospital Center, Brooklyn (United States of America)

8 More presentations in this session

Presentation thumbnail
Socioeconomic disparity in utilization of transcatheter aortic valve replacement
Associate Professor Y. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Demographics and clinical outcomes of flow-gradient patterns of aortic stenosis: an analysis of the CURRENT AS Registry-2.
Doctor T. Taniguchi (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Inter-ethnic heterogeneity in valvular morphology and aortopathy of a worldwide bicuspid aortic valve cohort referred for TAVR
Doctor M. Barki (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Clinical impact of transcatheter aortic valve implantation (TAVI) in frail patients: a single-center prospective study
Doctor D. Martinez Lopez (Alicante, ES)
Abstract Slides Video
Presentation thumbnail
Symptoms of Anxiety and Depression (SAD) in patients undergoing transcatheter aortic valve implantation. A multicentre Australian experience: The SAD-TAVI Study
Doctor A. Butala (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Diversity and specific populations in valvular heart disease

The Event

Event poster

ESC Congress 2024

2 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of adverse cardiac events in a large cohort of patients with antiphospholipid syndrome
thumbnail
Congress Presentation
Left-sided valvular heart disease and stroke outcomes: a nationwide cohort study from Sweden
thumbnail
Congress Presentation
Cardiovascular risk in rare autoimmune diseases, lessons from a primary antiphospholipid syndrome patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources